MX2022011972A - Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. - Google Patents

Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.

Info

Publication number
MX2022011972A
MX2022011972A MX2022011972A MX2022011972A MX2022011972A MX 2022011972 A MX2022011972 A MX 2022011972A MX 2022011972 A MX2022011972 A MX 2022011972A MX 2022011972 A MX2022011972 A MX 2022011972A MX 2022011972 A MX2022011972 A MX 2022011972A
Authority
MX
Mexico
Prior art keywords
uveitis
methods
macular edema
compositions
treatment
Prior art date
Application number
MX2022011972A
Other languages
English (en)
Inventor
Ronald Buggage
Karen W Chu
Kristine A Erickson
Dominique Mery-Mignard
Rafael Varona
Robert L Vitti
Sundaram Preethi Aavali Sridhara
Dit Genti Valérie Corp
Original Assignee
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology filed Critical Sanofi Biotechnology
Publication of MX2022011972A publication Critical patent/MX2022011972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona composiciones y métodos de tratamiento y de mejora de los síntomas de la uveítis y/o del edema macular usando un anticuerpo que se une específicamente al receptor de la interleucina-6 humana (hIL-6R).
MX2022011972A 2015-11-03 2018-05-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. MX2022011972A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250269P 2015-11-03 2015-11-03
EP16306166 2016-09-14
US201662408391P 2016-10-14 2016-10-14

Publications (1)

Publication Number Publication Date
MX2022011972A true MX2022011972A (es) 2022-10-20

Family

ID=57018106

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005589A MX2018005589A (es) 2015-11-03 2016-11-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2022011972A MX2022011972A (es) 2015-11-03 2018-05-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018005589A MX2018005589A (es) 2015-11-03 2016-11-03 Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.

Country Status (13)

Country Link
US (2) US10968278B2 (es)
EP (1) EP3371224A1 (es)
JP (4) JP7272794B2 (es)
KR (1) KR102930886B1 (es)
CN (1) CN108473583A (es)
AU (2) AU2016348418B8 (es)
BR (1) BR112018008900A8 (es)
CA (1) CA3003874A1 (es)
IL (1) IL319993A (es)
MX (2) MX2018005589A (es)
SG (1) SG11201803654TA (es)
TW (3) TW202339795A (es)
WO (1) WO2017079443A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP3371224A1 (en) 2015-11-03 2018-09-12 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
TW202233841A (zh) * 2020-10-28 2022-09-01 美商銳進科斯生物股份有限公司 用於眼適應症之載體化抗ＴＮＦ－α抗體
AU2023369998A1 (en) * 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
EP0783893B1 (en) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
US6046223A (en) 1996-02-26 2000-04-04 Advanced Research & Technology Institute Treatment of macular edema
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
AU2009246430B2 (en) * 2008-05-13 2015-07-02 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
NZ603191A (en) 2010-05-07 2015-02-27 Xoma Technology Ltd Methods for the treatment of il-1b related conditions
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
HK1211599A1 (en) * 2012-11-08 2016-05-27 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
WO2015077582A1 (en) 2013-11-22 2015-05-28 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
EP3371224A1 (en) 2015-11-03 2018-09-12 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Also Published As

Publication number Publication date
JP7581399B2 (ja) 2024-11-12
CA3003874A1 (en) 2017-05-11
CN108473583A (zh) 2018-08-31
SG11201803654TA (en) 2018-05-30
JP2023062062A (ja) 2023-05-02
MX2018005589A (es) 2018-11-09
EP3371224A1 (en) 2018-09-12
TW202339795A (zh) 2023-10-16
TWI786636B (zh) 2022-12-11
KR20180073680A (ko) 2018-07-02
US20210301027A1 (en) 2021-09-30
AU2016348418A1 (en) 2018-06-21
US20170166646A1 (en) 2017-06-15
AU2016348418A8 (en) 2023-10-19
AU2023233110A1 (en) 2023-10-05
WO2017079443A1 (en) 2017-05-11
AU2016348418B2 (en) 2023-10-12
TW201729828A (zh) 2017-09-01
JP2018532804A (ja) 2018-11-08
JP2021193120A (ja) 2021-12-23
WO2017079443A8 (en) 2017-07-06
JP7272794B2 (ja) 2023-05-12
BR112018008900A2 (pt) 2018-11-06
JP2025020227A (ja) 2025-02-12
TWI729022B (zh) 2021-06-01
AU2016348418B8 (en) 2023-10-19
IL319993A (en) 2025-06-01
US10968278B2 (en) 2021-04-06
KR102930886B1 (ko) 2026-02-25
TW202138001A (zh) 2021-10-16
BR112018008900A8 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MX393740B (es) Anticuerpos contra alfa-sinucleina y sus usos.
EA201590388A1 (ru) Способы лечения таупатии
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX2024010027A (es) Anticuerpos contra el vih ampliamente neutralizantes y metodos de uso de ellos.
EA201592203A1 (ru) Способы лечения таупатии
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201791937A1 (ru) Противовоспалительные полипептиды
MX390653B (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença